GlassScriptPhysician profile
Kavitha Ganesan
NPI 1427402551
$2,470.28
in general payments reported to CMS, 2019-2025
29 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.86 · 2022: $204 · 2023: $275 · 2024: $828 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,848 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,848.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $438.59 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $284.11 | 2021-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $206.65 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $205.08 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $165.35 | 2023-2025 | |
| Nevro Corp. | $121.17 | 2024 | Senza |
| Insulet Corporation | $105.80 | 2024-2025 | Omnipod |
| Kyowa Kirin, INC. | $100.78 | 2023-2025 | Crysvita |
| Neurocrine Biosciences, INC. | $95.55 | 2024-2025 | |
| Medtronic, INC. | $94.91 | 2022-2024 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $82.05 | 2022-2025 | |
| Dexcom, INC. | $76.24 | 2022-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.92 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $64.43 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $63.42 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $41.14 | 2022-2023 | Mycapssa |
| Sequel Med Tech, LLC | $37.74 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $36.48 | 2024 | Resmetirom |
| Globus Medical, INC. | $24.34 | 2025 | Senza |
| Amphastar Pharmaceuticals, INC. | $19.90 | 2024 | Baqsimi |
| Alexion Pharmaceuticals, INC. | $16.93 | 2022 | |
| Soleno Therapeutics, INC. | $16.46 | 2025 | Vykat Xr |
| Ibsa Pharma INC. | $16.38 | 2023 | Tirosint, Licart |
| Radius Health, INC. | $16.18 | 2024 | Tymlos |
| Pfizer INC. | $14.31 | 2022 | |
| Beta Bionics, INC. | $13.50 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Chiesi USA, INC. | $13.48 | 2025 | Mycapssa |
| Recordati_rare_diseases_inc. | $12.70 | 2022 | |
| Eusa Pharma (US) LLC | $12.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Ganesan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.